Is Pacira BioSciences (PCRX) overvalued or fairly valued?

MarketChacha shows Pacira BioSciences's valuation in context — a trailing P/E of about 131.8, a forward P/E of about 7.6, a price-to-book of about 1.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Pacira BioSciences's revenue?

Pacira BioSciences reported revenue of $726.4M for FY2025, with net profit of $7.0M, per official filings.

What is the share price of Pacira BioSciences (PCRX)?

Pacira BioSciences last traded at $26.35 (-0.9% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Pacira BioSciences

PCRX · NYSE · Healthcare · United States

Snapshot

TickerPCRX

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees825

HeadquartersBrisbane, United States

Websitewww.pacira.com

Filings tracked14

About Pacira BioSciences

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Who owns it

Insiders1.7%
Institutions98.3%
Public & other0.0%

348 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.82%
Doma Perpetual Capital Management LLC6.97%
Vanguard Portfolio Management LLC6.04%
Dimensional Fund Advisors LP5.28%
State Street Corporation5.17%
Shaw D.E. & Co., Inc.4.89%
Renaissance Technologies, LLC4.35%
Vanguard Capital Management LLC4.24%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 5.2 points over the period — profitability is trending down.

Net margin trend6.2% → 1.0%

Margin has compressed by about 5.2 points over the period — profitability is trending down.

Return on equity1.0%

Latest ROE of 1.0% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 4% · PAT -59%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $201.4M · EPS 0.84

Est. earnings growth +47.6%

Next fiscal year

Rev $788.2M · EPS 3.45

Est. earnings growth +19.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$726.4M

Net margin

1.0%

ROE

1.0%

Revenue CAGR (2y)

+3.7%

Profit CAGR (2y)

-59.1%

EPS (FY2025)

0.16

Net profit (FY2025)

$7.0M

Ask MarketChacha about PCRX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$726.4M	$7.0M	0.16	1.0%	1.0%
FY2024	$701.0M	$-99.6M	-2.15	-14.2%	-12.8%
FY2023	$675.0M	$42.0M	0.89	6.2%	4.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$192.4M	$4.7M	0.12	2.4%
2026Q1	$177.4M	$2.9M	0.07	1.6%
2025Q3	$179.5M	$5.4M	0.12	3.0%
2025Q2	$181.1M	$-4.8M	-0.11	-2.7%
2025Q1	$168.9M	$4.8M	0.10	2.8%
2024Q3	$168.6M	$-143.5M	-3.11	-85.1%
2024Q2	$178.0M	$18.9M	0.39	10.6%
2024Q1	$167.1M	$9.0M	0.19	5.4%
2023Q3	$163.9M	$10.9M	0.23	6.6%
2023Q2	$169.5M	$25.8M	0.51	15.2%
2023Q1	$160.3M	$-19.5M	-0.43	-12.2%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/4/2026material
10-Q — 10-Q - PCRX - 06.30.2026
SEC8/4/2026
8-K — Material agreement, Reg FD disclosure, Exhibits
SEC6/30/2026material
8-K — Executive/director change, Shareholder vote results, Other events, Exhibits
SEC6/11/2026material
8-K — Results of operations, Exhibits
SEC4/30/2026material
10-Q — 10-K - PCRX - 03.31.2026
SEC4/30/2026
8-K — Results of operations, Exhibits
SEC2/26/2026material
10-K — 10-K - PCRX - 12.31.2025
SEC2/26/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC1/28/2026material
8-K — Results of operations, Exhibits
SEC1/8/2026material

2025

8-K — Results of operations, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC8/5/2025material
10-Q filing
SEC8/5/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.